Welcome to LookChem.com Sign In|Join Free
  • or
HENAN SUNLAKE ENTERPRISE CORPORATIONCAS:164656-23-9 C27H30F6N2O2 Dutasteride//file1.lookchem.com/300w/substances/2022-02-14-04/82829e09-66c3-4fbd-94cc-cc986877290d.png
qq

Communicate with Supplier:

Ms. summer
Ms. summer: What can I do for you?

CAS:164656-23-9 C27H30F6N2O2 Dutasteride CAS NO.164656-23-9

Min.Order Quantity:
500 Gram
Purity:
99%
Port:
depend on clients require
Payment Terms:
L/C,D/A,D/P,T/T,MoneyGram,Other

Add to Inquiry Cart

Product Details

Keywords

  • CAS:164656-23-9 C27H30F6N2O2 Dutasteride
  • CAS:164656-23-9 C27H30F6N2O2 factory price high purity 99%
  • CAS:164656-23-9 C27H30F6N2O2 technical grade or OLED grade

Quick Details

  • ProName: CAS:164656-23-9 C27H30F6N2O2 Dutasteri...
  • CasNo: 164656-23-9
  • Molecular Formula: C27H30F6N2O2
  • Appearance: white poweder
  • Application: CAS:164656-23-9 C27H30F6N2O2 technical...
  • DeliveryTime: 5 working days after cash deposit
  • PackAge: Plastic vacuum packaging bag or bucket
  • Port: depend on clients require
  • ProductionCapacity: 1 Metric Ton/Day
  • Purity: 99%
  • Storage: under the cool and dry area
  • Transportation: by express or by sea
  • LimitNum: 500 Gram
  • Grade: Industrial Grade,Food Grade,Pharma Gra...

Superiority

dutasteride basic information
medicines to treat benign prostatic hyperplasia clinical evaluation application
product name: dutasteride
synonyms: (5alpha,17beta)-n-{2,5-bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-l-ene-17-carboxamide;dutasteride;gg-745, gi-198745,;5α,17β)-n-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4- aza -androst-1-ene-17-carboxamide;duagen;(5a,17)-n-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-azaandrost-1-ene-17-carboxamide;avodart;gi 198745
cas: 164656-23-9
mf: c27h30f6n2o2
mw: 528.53
einecs:
product categories: miscellaneous biochemicals;all inhibitors;inhibitors;intermediates & fine chemicals;pharmaceuticals;steroids;steroid and hormone;hormone drugs;api
mol file: 164656-23-9.mol
dutasteride structure
dutasteride chemical properties
mp 242-250°c
storage temp. -20°c freezer
safety information
msds information
dutasteride usage and synthesis
medicines to treat benign prostatic hyperplasia on october 9, 2002, dutasteride that was developed by gsk was approved by the us food and drug administration for the use in the treatment of prostate enlargement.
on june 19, 2008, gsk announced that the fda approved for the combination of idutasteride and tamsulosin in the treatment of prostate hyperplasia.
in china, on of two elderly men over the age of 60 have benign prostatic hyperplasia. it can cause urinary tract symptoms, including significant rise in frequency of urination, thin urine flow, bladder emptying difficulties, as well as nocturia. it even can cause serious complications, like acute urinary retention, reduce the patients’ life quality, and affect their social life.
dutasteride is the first and the only dual 5α reductase inhibitor to be used in the treatment of prostatic hyperplasia. it can improve urinary system symptom, reduce the onset of acute urinary retention and the risk of prostate surgery. tamsulosin is α receptor blockers. it can improve the symptom of prostate hyperplasia.
the human body has both type i reductase and type ii 5α reductase. type ii mainly exists in the prostate. and type i mainly distributes in the liver and skin. 5α reductase is the important reason that leads benign hyperplastic prostate disease continuous developing. it can make testosterone in patients’ prostate transform to dht with stronger activity, which can cause prostate cells hyperplasia and prostate hypertrophy. therefore, the inhibition of 5α reductase is the key to treat benign prostatic hyperplasia. and dutasteride can inhibit the type i and type ii 5α reductase at the same time. through this double inhibition mechanism, dutasteride can rapidly and continuously decrease prostate volume, significantly improve the urinary symptoms, reduce the risk of acute urinary retention and related prostate surgery, and bring benefit to patients with persistent, especially the middle and severe patients with benign prostatic hyperplasia.
the above information is edited by the chemicalbook geqian.
clinical evaluation the approval of the us food and drug administration bases on a multicenter randomized double-blind controlled clinical study for two years -- the first long-term evaluation of the combination of dutasteride and alpha blockers in clinical research. the patients include moderate and severe prostate hyperplasia patients (age is greater than or equal to 50, prostatic volume (pv) ≥ 30cc, serum prostate specific antigen (psa) level is 1.5 ~ 10 ng/ml, 5 ml/s < maximum urinary flow rate (qmax) ≤15 ml/s, the minimum urine output ≥ 125 ml, the international prostate symptom score (ipss) ≥ 12). patients firstly take placebo for four weeks, and then randomly take both dutasteride 0.5 mg/day and tamsulosin 0.4 mg/day, or only take dutasteride 0.5 mg/day, tamsulosin 0.4 mg/day.
the clinical study shows that the treatment effect of the combination of dutasteride is better than single treatment after twelve and twenty-four months. the most common adverse reactions of this product are impotence, decreased libido, breast disease (including breast augmentation, swelling), ejaculatory dysfunction, and dizziness.
application dutasteride is 5α reductase inhibitor.
chemical properties white crystalline solid
usage used in the treatment of benign prostatic hyperplasia. dual inhibitor of 5a-reductase isoenzymes type 1 and 2; structurally related to finasteride.
usage used in the treatment of benign prostatic hyperplasia. dual inhibitor of 5α-reductase isoenzymes type 1 and 2; structurally related to finasteride.
usage antihypertensive, ace inhiibitor
usage dutasteride is a dual inhibitor of 5α-reductase isoenzymes type 1 and 2; structurally related to finasteride (f342000). dutasteride is used in the treatment of benign prostatic hyperplasia.

Details

ucts

dutasteride

product categories: pharmaceuticals / api / hormonic drug
english name: dutasteride
cas no.: 164656-23-9
molecular weight: 528.53
molecular formula: c27h30f6n2o2
standard: ep8
package: 5kg/tin, 25kg/drum
appearance: white or light yellow powder, the melting point is 242~250℃，insoluble in water, soluble in ethanol(44mg/ml), methyl alcohol（64mg/ml), polyethylene glycol 400(4mg/ml)。
application: treatment of prostate disease and male hair loss
structural formula:

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

Related Products

Related Keywords

Inquiry Cart 0